- 中国精品科技期刊
- 中国高校百佳科技期刊
- 中国中文核心期刊
- 中国科学引文数据库核心期刊
| Citation: |
RONG Guangmei, WANG Xun, LIU Xiaodong, et al. Effects of bile duct ligation on function and expression of OCT1/2 on the blood-brain barrier in rats and their mechanisms[J]. J China Pharm Univ, 2024, 55(4): 504 − 511. DOI: 10.11665/j.issn.1000-5048.2023122204
|
This study investigated the effects of bile duct ligation (BDL)-induced liver injury on the function and expression of organic cation transporter 1/2 (OCT1/2) at blood brain barrier (BBB) and their potential mechanisms. BDL rat model was constructed, and physiological and biochemical parameters, BBB integrity, cortical OCT1/2 protein expression and function, and plasma chenodeoxycholic acid (CDCA) level were then examined by kits, Western blot, and LC-MS. Physiological and biochemical parameters, plasma bile acid levels, and cortical OCT1/2 protein expression were determined in rats after ig administration of CDCA for 14 d. The results showed that serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) levels increased, plasma CDCA level increased, the brain-to-blood concentration ratio (Kp) of amantadine decreased, while cortical Claudin-5 and Occludin did not significantly change, OCT1 expression was downregulated, while OCT2 did not significantly change in BDL rats. Serum AST, ALT, and ALP levels did not significantly change, plasma CDCA level increased, cortical OCT1 expression was downregulated, and OCT2 did not significantly change in rats after ig administration of CDCA. This study suggests that downregulation of OCT1 function and expression at BBB of BDL rats is related to elevated CDCA in plasma.
| [1] |
Wu T, Sheng Y, Qin YY, et al. Bile duct ligation causes opposite impacts on the expression and function of BCRP and P-gp in rat brain partly via affecting membrane expression of ezrin/radixin/moesin proteins[J]. Acta Pharmacol Sin, 2021, 42(11): 1942-1950. doi: 10.1038/s41401-020-00602-3
|
| [2] |
Liu X. Drug transporters in drug disposition, effects and toxicity [M]. Singapore: Springer Singapore, 2019, 1141 : 101-202.
|
| [3] |
Jensen O, Matthaei J, Blome F, et al. Variability and heritability of thiamine pharmacokinetics with focus on OCT1 effects on membrane transport and pharmacokinetics in humans[J]. Clin Pharmacol Ther, 2020, 107(3): 628-638. doi: 10.1002/cpt.1666
|
| [4] |
Koepsell H. Organic cation transporters in health and disease[J]. Pharmacol Rev, 2020, 72(1): 253-319. doi: 10.1124/pr.118.015578
|
| [5] |
Sharma S, Zhang Y, Akter KA, et al. Permeability of metformin across an in vitro blood-brain barrier model during normoxia and oxygen-glucose deprivation conditions: role of organic cation transporters (Octs)[J]. Pharmaceutics, 2023, 15(5): 1357. doi: 10.3390/pharmaceutics15051357
|
| [6] |
Liotta EM, Kimberly WT. Cerebral edema and liver disease: classic perspectives and contemporary hypotheses on mechanism[J]. Neurosci Lett, 2020, 721: 134818. doi: 10.1016/j.neulet.2020.134818
|
| [7] |
Hong SJ, Li S, Meng XY, et al. Bile duct ligation differently regulates protein expressions of organic cation transporters in intestine, liver and kidney of rats through activation of farnesoid X receptor by cholate and bilirubin[J]. Acta Pharm Sin B, 2023, 13(1): 227-245. doi: 10.1016/j.apsb.2022.06.010
|
| [8] |
Nies AT, Koepsell H, Winter S, et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver[J]. Hepatology, 2009, 50(4): 1227-1240. doi: 10.1002/hep.23103
|
| [9] |
Takeda M, Takei H, Suzuki M, et al. Bile acid profiles in adult patients with biliary atresia who achieve native liver survival after portoenterostomy[J]. Sci Rep, 2024, 14(1): 2492. doi: 10.1038/s41598-024-52969-6
|
| [10] |
Fitzinger J, Rodriguez-Blanco G, Herrmann M, et al. Gender-specific bile acid profiles in non-alcoholic fatty liver disease[J]. Nutrients, 2024, 16(2): 250. doi: 10.3390/nu16020250
|
| [11] |
Qin TT, Hasnat M, Wang ZW, et al. Geniposide alleviated bile acid-associated NLRP3 inflammasome activation by regulating SIRT1/FXR signaling in bile duct ligation-induced liver fibrosis[J]. Phytomedicine, 2023, 118: 154971. doi: 10.1016/j.phymed.2023.154971
|
| [12] |
Kaler B, Karram T, Morgan WA, et al. Are bile acids involved in the renal dysfunction of obstructive jaundice? An experimental study in bile duct ligated rats[J]. Ren Fail, 2004, 26(5): 507-516. doi: 10.1081/JDI-200031753
|
| [13] |
Liang LM, Zhou JJ, Xu F, et al. Diabetes downregulates peptide transporter 1 in the rat jejunum: possible involvement of cholate-induced FXR activation[J]. Acta Pharmacol Sin, 2020, 41(11): 1465-1475. doi: 10.1038/s41401-020-0408-4
|
| [14] |
Sweeney MD, Zhao Z, Montagne A, et al. Blood-brain barrier: from physiology to disease and back[J]. Physiol Rev, 2019, 99(1): 21-78. doi: 10.1152/physrev.00050.2017
|
| [15] |
Huang J, Ding JY, Wang XH, et al. Transfer of neuron-derived α-synuclein to astrocytes induces neuroinflammation and blood-brain barrier damage after methamphetamine exposure: involving the regulation of nuclear receptor-associated protein 1[J]. Brain Behav Immun, 2022, 106: 247-261. doi: 10.1016/j.bbi.2022.09.002
|
| [16] |
Jin HE, Hong SS, Choi MK, et al. Reduced antidiabetic effect of metformin and down-regulation of hepatic Oct1 in rats with ethynylestradiol-induced cholestasis[J]. Pharm Res, 2009, 26(3): 549-559. doi: 10.1007/s11095-008-9770-5
|
| [17] |
Redeker KM, Jensen O, Gebauer L, et al. Atypical substrates of the organic cation transporter 1[J]. Biomolecules, 2022, 12(11): 1664. doi: 10.3390/biom12111664
|
| [18] |
Kim MH, Maeng HJ, Yu KH, et al. Evidence of carrier-mediated transport in the penetration of donepezil into the rat brain[J]. J Pharm Sci, 2010, 99(3): 1548-1566. doi: 10.1002/jps.21895
|
| [19] |
Wang JG, Liu B, Sun FJ, et al. Histamine H3R antagonist counteracts the impaired hippocampal neurogenesis in lipopolysaccharide-induced neuroinflammation[J]. Int Immunopharmacol, 2022, 110: 109045. doi: 10.1016/j.intimp.2022.109045
|
| [1] | ZHANG Zhixing, DENG Hua, TANG Yun. Applications and challenges of artificial intelligence in the development of anticancer peptides[J]. Journal of China Pharmaceutical University, 2024, 55(3): 347-356. DOI: 10.11665/j.issn.1000-5048.2024040201 |
| [2] | HU Zi’ang, GAO Liming, YU Wenying. Advances in the application of artificial intelligence in nucleic acid drug development[J]. Journal of China Pharmaceutical University, 2024, 55(3): 335-346. DOI: 10.11665/j.issn.1000-5048.2024033101 |
| [3] | ZENG Hao, WU Guozhen, ZOU Wuxin, WANG Zhe, SONG Jianfei, SHI Hui, WANG Xiaojian, HOU Tingjun, DENG Yafeng. Optimization of Menin inhibitors based on artificial intelligence-driven molecular factory technology[J]. Journal of China Pharmaceutical University, 2024, 55(3): 326-334. DOI: 10.11665/j.issn.1000-5048.2024040904 |
| [4] | CHEN Baiyu, LYU Lunan, XU Xiaodi, ZHANG Ying, LI Wei, FU Wei. Reflections on improving drug success rates with AIDD and CADD[J]. Journal of China Pharmaceutical University, 2024, 55(3): 284-294. DOI: 10.11665/j.issn.1000-5048.2024011302 |
| [5] | PU Chengtao, GU Lingqian, CHEN Xingye, ZHANG Yanmin. Prediction of human intestinal absorption properties based on artificial intelligence[J]. Journal of China Pharmaceutical University, 2023, 54(3): 355-362. DOI: 10.11665/j.issn.1000-5048.2023032102 |
| [6] | XUE Feng, FENG Shuo, LI Jing. Application and prospect of artificial intelligence in antimicrobial peptides screening[J]. Journal of China Pharmaceutical University, 2023, 54(3): 314-322. DOI: 10.11665/j.issn.1000-5048.2023030901 |
| [7] | GU Zhihao, GUO Wenhao, YAO Hequan, LI Xuanyi, LIN Kejiang. Research progress of the screening and generation of lead compounds based on artificial intelligence model[J]. Journal of China Pharmaceutical University, 2023, 54(3): 294-304. DOI: 10.11665/j.issn.1000-5048.2023042201 |
| [8] | YU Zehao, ZHANG Leiming, ZHANG Mengna, DAI Zhiqi, PENG Chengbin, ZHENG Siming. Artificial intelligence-based drug development: current progress and future challenges[J]. Journal of China Pharmaceutical University, 2023, 54(3): 282-293. DOI: 10.11665/j.issn.1000-5048.2023041003 |
| [9] | WANG Chao, XIAO Fu, LI Miaozhu, PAN Ying, DING Xiao, REN Feng, ZHAVORONKOV Alex, WANG Yazhou. Application progress of artificial intelligence in the screening and identification of drug targets[J]. Journal of China Pharmaceutical University, 2023, 54(3): 269-281. DOI: 10.11665/j.issn.1000-5048.2023041102 |
| [10] | YAN Fangrong. Application and advance of artificial intelligence in biomedical field[J]. Journal of China Pharmaceutical University, 2023, 54(3): 263-268. DOI: 10.11665/j.issn.1000-5048.2023030304 |
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Total visits：292830
DownLoad: